Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
The combination of pharmacokinetic and pharmacodynamic monitoring of immunosuppressive drugs provides a novel method for the optimization of drug dosing. We chose to investigate this with the use of mycophenolic acid (MPA), an immunosuppressive drug that mediates its effect by the inhibition of inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo biosynthesis of purines. The relationship between MPA concentration in plasma, IMPDH activity in whole blood, and nucleotide concentration in lymphocytes was investigated in renal-transplant recipients, who were randomized to receive either mycophenolate mofetil (MMF) (n = 5) or azathioprine (AZA) (n = 7), in combination with cyclosporine and prednisone. Blood samples were collected throughout the dosing interval. Pharmacokinetic analysis revealed substantial variability among the patients in the absorption and clearance of MPA. An inverse relationship was found between the MPA concentration of IMPDH activity in whole blood. The peak concentration of MPA achieved at 1 hr after dosing resulted in approximately 40% inhibition of IMPDH activity. As the MPA concentration decreased throughout the dosing interval, there was a gradual restoration of IMPDH activity. The inhibition of IMPDH activity (P < 0.05) in MMF-treated patients as compared with the AZA-treated controls was maintained for approximately 8 hr after dosing. No statistically significant (P > 0.05) difference between the predose and the 12 hr postdose activity was observed. The concentrations of guanine nucleotides, GDP and GMP, were significantly lower than in the AZA-treated group at most of the time points after dosing; however, considerable variability was observed. The measurement of the pharmacodynamic response to immunosuppressive drugs may provide not only a mechanism to predict the most appropriate dosing regimen, but also a viable alternative to traditional therapeutic drug monitoring, by assessing the overall state of immunosuppression.
Langman
L J
LJ
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
LeGatt
D F
DF
Halloran
P F
PF
Yatscoff
R W
RW
D001379:Azathioprine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors / Q000097:blood; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D009173:Mycophenolic Acid / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011685:Purine Nucleotides / Q000097:blood
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D011685:Purine Nucleotides; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid; D001379:Azathioprine